Intermittent Low-Dose Ritlecitinib in Refractory Pediatric Alopecia Areata: A Case Report with Therapeutic Implications

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

An arthritis drug, Rinvoq, restores hair in some alopecia areata patients but is not effective for androgenetic alopecia. It is used for autoimmune-related skin disorders, but its high cost and lack of insurance coverage are issues.

An arthritis drug restored significant hair in people with alopecia areata, but it is not effective for male pattern baldness. The drug, Upadacitinib, has serious side effects and is expensive.

The user experienced side effects from a hair loss treatment and is considering using pyrilutamide, alfatradiol, and possibly minoxidil. They are unsure about starting minoxidil immediately or waiting to see the effects of the other treatments.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.